Table 2.

Patients and disease characteristics in discovery and validation cohorts

No. of patients (%)
Discovery cohort (n = 229)Validation cohort (n = 187)
Gender
    Female/male95/134 (42:58)78/109 (42:58)
Race
    White/non-white170/59 (74:26)0/187 (0:100)
Age (y, median)52.5 (20-75)49.0 (17-87)
Previous treatment prior to imatinib
    IFN98 (43)30 (16)
    Busulfan17 (7)0 (0)
    Cytarabine19 (8)0 (0)
    BMT12 (5)10 (5)
Newly diagnosed case
    De novo vs. previously treated115:114147:40
Disease duration from diagnosis (mo, median)4.3 (0-231)0.5 (0-114)
Disease stage
    CP203 (89)163 (90)
    AP23 (10)11 (6)
    BC3 (1)7 (4)
Cytogenetics
    t(9;22) only200 (87)163 (87)
    Additional abnormalities29 (13)*24 (13)
Maximum dose of imatinib
    400 mg/d210 (92)177 (94)
    600 mg/d17 (7)7 (4)
    800 mg/d2 (1)3 (2)
  • *Additional cytogenetic abnormalities were detected in the discovery population: −Y (n = 5); double Ph+ chromosome (n = 5); t(7;8) (n = 2); t(9;22;22) (n = 2); t(2;9;22) (n = 2); t(9;22;17) (n = 1); t(1;22;18) with inv(5) (n = 1); t(7;8) with +8 and +der(22) (n = 1); t(8;17) (n = 1); t(8;16) (n = 1); inv(9q) (n = 1); −18q (n = 1); t(12;16) (n = 1); t(3;19) (n = 1); t(4;6), 47-52, +X, +6, +8, +18, +19, +der(22) (n = 1); t(17;20), +der(17), +der(20) (n = 1); +8 (n = 1); −X (n = 1).

  • Additional cytogenetic abnormalities were detected in the discovery population: −Y (n = 3); t(7;9;22) (n = 1); t(8;9;22) (n = 1); t(9;22;11) (n = 1); t(9;22;14) (n = 1); t(9;22;17) (n = 1); t(9;22;19) (n = 1); t (4;22) with t(17;20) (n = 1); inv(3) (n = 1); inv(3) with t(12;17), del(7), der(9), add(9), −6, −13 (n = 1); der(9), del(9) (n = 1); del(7) with t(2;11) (n = 1); del(22q) (n = 1); +der(22) (n = 2); +der(22) with t(11;13). −18 (n = 1); +1 with der(1;15) (n = 1); +8 (n = 2); +8, +10, +13, +14, +22, der(22) (n = 1), +8, +der(22) (n = 1); = 12 (n = 1).